Last reviewed · How we verify
Tegaderm
At a glance
| Generic name | Tegaderm |
|---|---|
| Sponsor | Imperial College London |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Ellacor® Micro-coring® Following Best Practices on Technique and Post-Procedural Care (NA)
- Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service (NA)
- A Silver Lining in the VAD Sky (NA)
- Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU) (PHASE2)
- Peripheral Catheter Pressure Ulcer Prevention in Pediatry : Use of Compresses Versus Standard Care (NA)
- Effectiveness of a Zinc Oxide Adhesive Securement Device in the Fixation of Midline and Peripherally Inserted Central Catheters in Hospitalized Adult Patients (NA)
- Components of Chlorhexidine Gluconate Dressing (PHASE1)
- Central Venous Catheter vs Midline in Difficulty Access Patient - Pilot Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tegaderm CI brief — competitive landscape report
- Tegaderm updates RSS · CI watch RSS
- Imperial College London portfolio CI